Regulus Therapeutics

Yahoo Finance • 2 years ago

Regulus Therapeutics Announces Resignation of Board Member

SAN DIEGO, Dec. 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announc... Full story

Yahoo Finance • 2 years ago

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

IND accepted and first subject dosed in the Phase 1 Single-Ascending Dose (SAD) study of RGLS8429for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) RGLS8429 granted Orphan Drug Designation (ODD) from the U.S. Food a... Full story

Yahoo Finance • 2 years ago

Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call

SAN DIEGO, Aug. 4, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announce... Full story

Yahoo Finance • 3 years ago

Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call

SAN DIEGO, May 5, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced... Full story